Devonian Health Group Inc. (CVE:GSD – Get Free Report)’s share price traded down 23.5% during mid-day trading on Saturday . The stock traded as low as C$0.09 and last traded at C$0.13. 119,000 shares traded hands during trading, an increase of 588% from the average session volume of 17,288 shares. The stock had previously closed at C$0.17.
Devonian Health Group Trading Down 23.5%
The company has a debt-to-equity ratio of 16.36, a quick ratio of 7.82 and a current ratio of 1.07. The company’s fifty day simple moving average is C$0.16 and its 200-day simple moving average is C$0.17. The company has a market capitalization of C$19.27 million, a P/E ratio of -4.64 and a beta of 0.67.
Devonian Health Group Company Profile
Devonian Health Group Inc engages in the development of botanical drugs. Its lead product candidate is Thykamine, completed Phase IIa clinical trial product for the treatment of ulcerative colitis and atopic dermatitis. The company also develops Pantoprazole Magnesium for the treatment of gastric; Cleo-35 for the treatment of hormonal acne in women; and value-added products for dermo-cosmetics.
Recommended Stories
- Five stocks we like better than Devonian Health Group
- Insider Buying Explained: What Investors Need to Know
- 3 Overlooked Value Stocks Set to Surge as Rates Drop
- Market Cap Calculator: How to Calculate Market Cap
- Hims & Hers Stock Pushes to Highs on Healthcare Rate Cut Frenzy
- P/E Ratio Calculation: How to Assess Stocks
- After the Fed’s Rate Cut, PNC Could See a Mortgage Refinance Boom
Receive News & Ratings for Devonian Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Devonian Health Group and related companies with MarketBeat.com's FREE daily email newsletter.
